Checkpoint Therapeutics, Inc. (CKPT)

NASDAQ: CKPT · IEX Real-Time Price · USD
1.37
-0.08 (-5.21%)
May 18, 2022 12:32 PM EDT - Market open
Market Cap124.25M
Revenue (ttm)252,000
Net Income (ttm)-67.01M
Shares Out91.03M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume174,956
Open1.44
Previous Close1.44
Day's Range1.36 - 1.45
52-Week Range0.96 - 4.64
Beta1.63
AnalystsBuy
Price Target20.20 (+1,379.9%)
Earnings DateMay 12, 2022

About CKPT

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger...

IndustryBiotechnology
IPO DateJun 26, 2017
Employees14
Stock ExchangeNASDAQ
Ticker SymbolCKPT
Full Company Profile

Financial Performance

In 2021, CKPT's revenue was $268,000, a decrease of -74.93% compared to the previous year's $1.07 million. Losses were -$56.67 million, 145.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CKPT stock is "Buy." The 12-month stock price forecast is 20.2, which is an increase of 1,379.85% from the latest price.

Price Target
$20.2
(1,379.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines A...

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe Waivers remove requirement to conduct pediatric clinical studies to...

5 days ago - GlobeNewsWire

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line res...

5 days ago - GlobeNewsWire

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 20...

WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the res...

2 weeks ago - GlobeNewsWire

Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Other symbols:CRXTXSPA
3 weeks ago - PennyStocks

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members...

1 month ago - GlobeNewsWire

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial re...

1 month ago - GlobeNewsWire

2 Biotech Stocks That Could Be 10-Baggers in 2022

These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.

Other symbols:AXSM
3 months ago - The Motley Fool

Checkpoint Therapeutics to Participate in the B. Riley Securities' Virtual Oncology Conference

WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Ol...

3 months ago - GlobeNewsWire

Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients

Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patie...

3 months ago - Benzinga

Why Checkpoint Therapeutics Stock Is Heating Up Today

Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.

3 months ago - The Motley Fool

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Met...

WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topl...

3 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in P...

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiatio...

5 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial res...

6 months ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James O...

7 months ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James O...

8 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results f...

9 months ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...

10 months ago - GlobeNewsWire

Why Checkpoint Therapeutics Skyrocketed Today

One analyst becomes a fervent believer in the company's stock.

11 months ago - The Motley Fool

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metas...

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the completion of en...

1 year ago - GlobeNewsWire

4 Meme Penny Stocks To Watch As DogeCoin Rises

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other symbols:BTUEBON
1 year ago - PennyStocks

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results fo...

1 year ago - GlobeNewsWire

7 Penny Stocks That May Have Room to Run Higher

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other symbols:AGRXAQMSHEPAIFRXLLNW
1 year ago - InvestorPlace

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results ...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics Announces Formation of Scientific Advisory Board

Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology

1 year ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...

1 year ago - GlobeNewsWire